S-1: Applied DNA Sciences Pivots to BNB Crypto Strategy

Applied DNA Sciences is shifting its primary focus to a BNB-focused digital asset treasury strategy, backed by a private placement raising up to $57.6 million, despite ongoing financial losses and going concern doubts.

Summary

• Applied DNA Sciences (APDN) is undergoing a significant strategic shift, moving its primary focus from nucleic acid production solutions to a yield-oriented digital asset treasury strategy centered on Binance Coin (BNB).
• The company completed a private placement, raising $26.7 million in gross proceeds, with the potential for an additional $30.8 million from future warrant exercises, totaling up to $57.6 million.
• The proceeds from the private placement will primarily fund the development and implementation of the BNB Strategy, as well as for working capital and general corporate purposes.
• APDN has undertaken multiple restructuring plans, including a 27% workforce reduction in June 2025 and a further 60% reduction in October 2025, aiming for annualized cost savings of approximately $2.9 million.
• The company has ceased operations at Applied DNA Clinical Labs (ADCL) and is winding down its DNA Tagging and Security Products and Services segment.
• APDN reported a net loss of $7,088,306 for the fiscal year ended September 30, 2024, and a net loss from continuing operations of $9,585,822 for the nine months ended June 30, 2025.
• Cash and cash equivalents stood at $4,727,677 as of June 30, 2025, with negative operating cash flow of $9,141,688 for the nine months ended June 30, 2025.
• The company's common stock is listed on The Nasdaq Capital Market under the symbol BNBX, with a closing price of $3.80 per share on October 28, 2025.
• Two reverse stock splits were effected in 2025: a 1-for-50 split on March 14, 2025, and a 1-for-15 split on June 2, 2025, to regain Nasdaq compliance.

Sentiment

Score: 2

Explanation: The company faces severe financial challenges, including recurring net losses and substantial doubt about its ability to continue as a going concern. While a capital raise provides some liquidity, the strategic pivot to a highly volatile and speculative digital asset strategy, coupled with significant workforce reductions and the winding down of traditional business segments, introduces extreme risk and uncertainty. The long-term viability and profitability of this new strategy are unproven, making the overall outlook highly negative despite the capital infusion.

Positives

• Successfully raised $26.7 million in gross proceeds from a private placement, with potential for up to an additional $30.8 million from warrant exercises, providing a significant capital infusion.
• The company is actively implementing restructuring plans, including substantial workforce reductions (27% in June 2025, 60% in October 2025), projected to result in annualized cost savings of approximately $2.9 million.
• Maintains a biotechnology segment focused on nucleic acid production solutions (LineaDNA, LineaRNAP, LineaIVT) for biopharmaceutical and diagnostics sectors, which offers potential for future sales and licensing agreements.
• LineaDNA offers advantages over traditional plasmid-based DNA manufacturing, being cell-free, rapid, scalable, and requiring minimal purification steps.
• LineaRNAP is engineered for high mRNA yields, increased mRNA integrity, and reduced double-stranded RNA (dsRNA) contamination, a problematic byproduct in mRNA production.
• LineaIVT integrates LineaDNA and LineaRNAP to simplify mRNA workflows and significantly reduce dsRNA contamination (10x to 50x reduction).

Negatives

• The company has recurring net losses, with an accumulated deficit of $373,888,601 as of June 30, 2025, and a net loss of $9,988,942 for the nine months ended June 30, 2025.
• There is substantial doubt about the company's ability to continue as a going concern for one year from the issuance of the financial statements.
• The strategic shift to a BNB-focused digital asset treasury strategy is a new and unproven business model for the company, with minimal operating history in cryptocurrencies, blockchain validation, or decentralized finance services.
• Significant workforce reductions (totaling 39% since January 2025, with a 60% reduction in October 2025) indicate severe financial distress and a drastic change in business operations.
• Product revenue decreased by 12% for FY2024 compared to FY2023, primarily due to declines in DNA Tagging and Security Products and Services.
• Clinical laboratory service revenue decreased by 88% for FY2024 compared to FY2023, mainly due to the cessation of COVID-19 testing services.
• Gross profit decreased by 82% for FY2024, with the gross profit percentage declining from 41% to 30%, primarily due to decreased testing volumes.
• The company has faced multiple Nasdaq minimum bid price deficiency notifications and has undergone two reverse stock splits in 2025 (1-for-50 and 1-for-15) to maintain listing compliance, indicating significant stock price underperformance.

Risks

• May not successfully implement its new BNB digital treasury strategy or achieve anticipated growth objectives.
• Stockholders may suffer substantial dilution if certain provisions in the May 2024 Series A Warrants, Series E Warrants, Advisory Warrants, Placement Agent Warrants, or Consultant Warrants are utilized, especially through cashless exercises.
• Sales of a significant number of common stock shares in public markets, or the perception of such sales, could depress the market price of common stock.
• Management has broad discretion in using offering proceeds, which may not yield a return or align with investor expectations.
• Inability to raise sufficient additional capital on acceptable terms could hinder expansion of BNB reserves and adversely affect liquidity, financial condition, and growth prospects.
• Failure to maintain compliance with Nasdaq listing standards could lead to delisting, negatively impacting business, capital raising ability, market price, and liquidity.
• The further development and acceptance of the BNB Chain and other cryptocurrency networks are uncertain and subject to various difficult-to-evaluate factors.
• Digital asset trading platforms are relatively new, largely unregulated, and may not comply with existing regulations, exposing the company to risks of fraud, manipulation, and market instability.
• The availability of spot exchange-traded products (ETPs) and futures exchange-traded funds (ETFs) for BNB could adversely affect the market price of the company's common stock.
• Disruption of the Internet could affect cryptocurrency network operations, impacting the cryptocurrency industry and the price of common stock.
• The trading prices of digital assets, including BNB, have experienced extreme volatility and may continue to do so, potentially leading to substantial losses on digital asset holdings.
• Subject to regulatory developments related to cryptocurrencies, which could adversely affect business, financial condition, results of operations, and common stock price, including potential classification of BNB as a security.
• Loss or theft of private keys or breaches of digital wallets could result in permanent loss of BNB and materially adversely affect the business.
• Competition from central bank digital currencies (CBDCs) and emerging payments initiatives could adversely affect the value of BNB.
• The emergence or growth of other digital assets could negatively impact the price of BNB.
• Reliance on open-source code by digital asset networks exposes the company to risks related to competitive networks, code maintenance failures, and security vulnerabilities.
• Lack of legal recourse and insurance for digital assets increases the risk of total loss in the event of theft or destruction.
• The U.S. federal income tax treatment of digital asset transactions is unclear and could result in adverse tax consequences.
• State, local, and non-U.S. tax treatment of digital assets is unclear and could result in adverse tax consequences.
• BNB and BNB Chain have links to, and may be controlled by, Binance and its principals, subjecting the company to counterparty, reputational, and regulatory risks outside its control.
• The value of common stock depends on the development and acceptance of the BNB Chain; slowing or stopping of its development could adversely affect investment.
• If validators exit the BNB Chain, it could increase the likelihood of a malicious actor obtaining control, negatively affecting BNB price and network confidence.
• BNB transactions are irrevocable, and stolen or incorrectly transferred BNB may be irretrievable, leading to potential losses.
• The BNB Chain's decentralized governance structure may negatively affect its ability to grow and respond to challenges.
• Risks relating to the potential compromise of BNB Chain security by emerging technologies, including artificial intelligence and quantum computing.
• Any name change and associated rebranding initiative by BNB core developers may not be favorably received, negatively impacting BNB value.
• Reliance on banks, financial institutions, and BNB exchanges located outside the United States may expose assets to heightened risks due to differing regulatory oversight and insolvency regimes.
• The company's BNB strategy may subject it to enhanced regulatory oversight, including potential scrutiny from the SEC or other agencies.
• Reliance on third-party custodians, trading platforms, and other counterparties to acquire, secure, stake, and dispose of BNB carries risks of failure or malfeasance.
• Concentration in a single digital asset (BNB) exposes the company to unique liquidity risks, especially during market stress.
• Concentration of BNB holdings across a limited number of protocols or validators may expose the company to heightened counterparty and systemic risks.
• Potential inconsistencies between the stated intentions and future actions of Binance and its related entities could adversely affect BNB value and liquidity.
• Historical financial statements do not reflect the potential variability in earnings from digital asset holdings, making it difficult to evaluate future prospects.
• Digital asset lending arrangements may expose the company to risks of borrower default, operational failures, and cybersecurity threats.
• Significant competition in the growing digital asset industry could adversely affect the company's business.
• The recently enacted GENIUS Act for stablecoins could materially impact borrowing or investing in stablecoins, requiring significant changes and incurring costs.
• Instability in other stablecoins could reduce trust in stablecoins borrowed or invested by the company, leading to operational and reputational challenges.
• An executive of the Services Provider (Patrick Horsman) was a party to litigation and counter defamation claims, and a principal of the Services Provider has been subject to regulatory actions with FINRA, posing reputational and financial risks.

Future Outlook

The company's current strategy is to primarily focus resources on its BNB-focused treasury strategy, which includes accumulating BNB tokens and implementing yield generation strategies such as staking, restaking, and liquid staking. The company acknowledges no assurance can be given that this strategy will be successful. The company also plans to continue advancing its nucleic acid production solutions to support potential future sales and/or licensing agreements.

Management Comments

• Clay Shorrock was appointed Chief Executive Officer and President, effective September 29, 2025.
• Judith Murrah resigned as CEO and President, effective September 29, 2025, and will remain Chairperson of the Board and a Board member.
• Dr. James A. Hayward retired as Chairman and Chief Executive Officer, effective June 18, 2025.
• Ms. Murrah voluntarily agreed to a 15% temporary reduction in her annual base salary in connection with the company's efforts to reduce ongoing operating expenses.
• Mr. Shorrock and Ms. Jantzen will each receive an annual base salary of $400,000, a one-time cash bonus of $175,000 and $150,000 respectively, and stock options with a grant-date fair market value of $200,000.

Industry Context

Applied DNA Sciences is pivoting from its traditional biotechnology focus on nucleic acid production and diagnostic services to a digital asset treasury strategy centered on BNB, the native cryptocurrency of the Binance blockchain. This move places the company in the rapidly evolving and highly volatile cryptocurrency industry, which is characterized by regulatory uncertainties, technological competition, and market volatility. The BNB ecosystem, while growing with DeFi applications and institutional interest, faces risks related to its links with Binance, potential classification of BNB as a security, and susceptibility to market manipulation and security breaches. This strategic shift is a departure from the company's historical biotech operations and aligns it with companies exploring digital asset investments, a trend that has seen increased scrutiny from regulators.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• No pending litigation involving the company at this time.
• U.S. regulators have scrutinized burn mechanisms in past enforcement actions, with the SEC citing issuer-controlled burn programs as evidence of efforts to influence a cryptocurrency's value consistent with securities characteristics. If regulators were to reach a similar conclusion regarding BNB's burn mechanism, it could increase the likelihood that BNB would be classified as a security and subject to heightened regulatory restrictions, adversely affecting its liquidity and price.
• The SEC filed complaints against Binance Holdings Ltd. and Coinbase, Inc. in June 2023, alleging operation as unregistered securities exchanges, brokers, dealers, and clearing agencies (though these complaints were recently dismissed).
• The SEC filed a complaint against Payward Inc. and Payward Ventures Inc. (Kraken) in November 2023, alleging operation as an unregistered securities exchange, broker, dealer, and clearing agency (though these complaints were recently dismissed).
• Binance Holdings Ltd. and its then chief executive officer reached a settlement with the Department of Justice, CFTC, Office of Foreign Asset Control, and Financial Crimes Enforcement Network in November 2023 for charges involving violations of U.S. laws governing money laundering, sanctions, and registration.
• Patrick Horsman, a founder and director of the Services Provider and the company's Chief Investment Officer, is a defendant in a litigation (Lev. v. Horsman, Dreyer, Schiff, Integrated Ag XI LLC, et al.) stemming from the 2019 collapse of the CBD industry. He has filed two defamation lawsuits against the investor.
• A principal of the Services Provider has been the subject of regulatory actions with FINRA, including a violation of the FINRA rule prohibiting purchasing a new issue in any account in which such person associated with a member has a beneficial interest, resulting in a Letter of Acceptance, Waiver & Consent.

Related Party Transactions

• Patrick Horsman, an affiliate of Cypress Management LLC (the Strategic Advisor) and Cypress LLC (the Services Provider), was appointed Chief Investment Officer of the company on October 1, 2025, receiving monthly compensation of $29,167.
• Cypress Management LLC provides strategic advice, guidance, and technical advisory services to the company for an initial term of five years, receiving Advisory Warrants to purchase 1,986,634 shares of common stock and a monthly fee of $60,000.
• Cypress LLC, a Puerto Rico limited liability company, was appointed by the company to provide discretionary asset management services for the BNB Strategy for an initial term of five years, compensated by a fixed-rate management fee of 1/12 of 1.25% per annum of net asset value and an incentive fee of 10% on net returns.
• Ground Tunnel Capital LLC (the Consultant) entered into consulting arrangements on September 23, 2025, to provide advisory and marketing services and premium sponsorship benefits at SALT conferences for three years, receiving a fee of $1,000,000 upfront and $250,000 quarterly from December 2025 until September 2027, plus Consultant Warrants to purchase 209,119 shares of common stock.
• Patrick Horsman IRA Investment Trust is a Selling Stockholder in this offering and a principal of Patrick Horsman.
• James Haft is an adviser to Cypress Management LLC and a Selling Stockholder.
• John Lipman is an employee of Lucid Capital Markets, LLC, the placement agent for the Private Placement, and is a Selling Stockholder.
• Lucid Capital Markets, LLC received Placement Agent Warrants to purchase 403,236 shares of common stock in connection with the Private Placement.

Stakeholder Impact

• **Shareholders:** Face substantial dilution risk from warrant exercises and potential future equity offerings. The value of their investment is highly dependent on the volatile price of BNB and the success of an unproven digital asset strategy. Delisting from Nasdaq remains a risk, which would negatively impact liquidity and market price. The company's going concern doubt poses a significant risk of total loss.
• **Employees:** Have experienced significant workforce reductions (39% total since January 2025, with a 60% reduction in October 2025), indicating job insecurity and a shift in company focus away from traditional biotech roles.
• **Customers (Biotech):** The company continues to advance its nucleic acid production solutions, which could benefit customers in biopharmaceutical and diagnostics sectors through improved DNA/RNA manufacturing technologies. However, the primary focus shift to BNB may divert resources from this segment.
• **Customers (Former DNA Tagging/MDx Testing):** The DNA Tagging and Security Products and Services business is winding down, and MDx Testing Services (ADCL) have ceased operations, impacting customers who relied on these services.
• **Creditors:** The company's recurring net losses and going concern doubt increase credit risk. The capital raise provides some relief, but the highly speculative nature of the new BNB strategy could impact the company's ability to meet future obligations.
• **Suppliers:** May face reduced demand from the winding down of traditional business segments and potential changes in procurement related to the new digital asset strategy.

Next Steps

• Continue the development and implementation of the BNB Strategy, including accumulating BNB tokens and generating yield through staking, restaking, and liquid staking.
• Seek stockholder approval for the exercisability of Crypto Pre-Funded Warrants and Series E-2 Warrants, as required by Nasdaq listing rules.
• Complete the reduction-in-force by the end of October 2025 and record associated charges in the first quarter of fiscal 2026.
• Continue advancing nucleic acid production solutions to support potential future sales and/or licensing agreements with third-party partners.
• Monitor and comply with Nasdaq listing standards to avoid delisting, potentially through further reverse stock splits if necessary.
• Address the ongoing regulatory uncertainties and evolving legal framework surrounding digital assets, particularly the potential classification of BNB as a security.

Key Dates

Recommendation

The company is in a precarious financial position, evidenced by recurring net losses, an accumulated deficit of over $373 million, and explicit 'substantial doubt about its ability to continue as a going concern.' While a capital raise of up to $57.6 million provides some liquidity, the company's strategic pivot from biotechnology to a 'yield-oriented digital asset treasury strategy centered on BNB' is an extreme and highly speculative shift. This new strategy is unproven for the company, operates in a largely unregulated and extremely volatile market (cryptocurrencies), and introduces significant new risks, including dependence on Binance and potential regulatory classification of BNB as a security. The company has also undergone drastic workforce reductions and exited established business segments, indicating a desperate attempt to find a viable path forward. For a seasoned investor, the combination of severe financial distress, high operational risk, and a speculative, unproven business model in a volatile industry warrants a 'strong sell' recommendation. The risks far outweigh any potential upside from the capital infusion or the new strategy.

Keywords

BNB Strategy, Cryptocurrency, Digital Assets, Biotechnology, Nucleic Acid Production, SEC Filing, S-1 Registration, Warrants, Private Placement, Nasdaq Delisting Risk, Financial Restructuring, Going Concern, LineaRx, DNA Manufacturing, mRNA Therapeutics, DeFi, Binance Chain, Stock Dilution